Avid Bioservices Inc (CDMO)

[entdoc]

Saturday nite perspective: Holding pattern. Consolidation after recent tripling of price. Relative price flatness this week. 4 million shares/day average in past ten days. That means $3.5 million spent buying, and an equal number sold. That equals 6000 shares of Apple bought/day, and Apple traded about 16000 shares/day average in that ten day period. Relatively, Perigrine remains either untouchable or unknown. At this point a dearth of stellar trial numbers for a treatment strategy of great sensibility, and Bavi's inventor, PPHM management, rumor, and bulls of various persuasions/expertise seem to be driving the stock price from a half dollar to almost three in as many weeks. It isn't stellar numbers. Will it happen--fulfillment of the hope and rumor that end-stage lung cancer patients treated with Bav+ standard of care chemotherapy are surviving longer than those without Bavi in the treatment mix? Bavi potential remains mind-boggling. The most compelling part of the standard of care narrative is that none of the most informed actors in the story--inventor and management--have ever before come out so strongly with an implied promise of success. Will Bavi live up to that [now] promise? Interesting and interestinger.